Jane Cai, MD
Geriatric Medicine · Lady Lake, FLNPI 1437164944
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Amgen at 28.7% of the total. Reporting peaked in 2019 at $1,458 and has fallen 66.6% since, to $486 in 2025. Among geriatric medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $25.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Amarin Pharma, Inc.$468
- Eisai Inc.$293
- Sanofi-aventis U.S. LLC$272
- Novartis$199
- Boehringer Ingelheim$193
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,63299%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 55 | $1,340 |
| Amarin Pharma, Inc. | 23 | $468 |
| Eisai Inc. | 9 | $293 |
| Sanofi-aventis U.S. LLC | 8 | $272 |
| Novartis | 11 | $199 |
| Boehringer Ingelheim | 2 | $193 |
| Kowa Pharmaceuticals America, Inc. | 11 | $163 |
| GSK | 5 | $161 |
| Lilly USA, LLC | 3 | $161 |
| Pfizer | 9 | $153 |
| AstraZeneca | 3 | $149 |
| Regeneron Healthcare Solutions, Inc. | 7 | $143 |
| Abbott | 2 | $135 |
| Johnson & Johnson | 4 | $119 |
| E.r. Squibb & Sons, L.L.C. | 1 | $102 |
| Novo Nordisk | 2 | $90 |
| Esperion Therapeutics, Inc. | 4 | $80 |
| Sumitomo Pharma America, Inc. | 3 | $67 |
| AbbVie(2 entities) | 3 | $56 |
| Boston Scientific | 1 | $40 |
| Merck | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Radius Health, Inc. | 2 | $34 |
| Exact Sciences | 2 | $30 |
| GE HealthCare | 1 | $25 |
| IBSA Pharma Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Life Molecular Imaging Ltd | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,663 in reported general payments places this provider in the 90th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 152 | $180,711 |
| VascepaIcosapent Ethyl | 85 | $65,920 |
| OzempicSemaglutide | 30 | $47,942 |
| EliquisApixaban | 26 | $42,401 |
| Praluent PenAlirocumab | 28 | $26,066 |
| MyrbetriqMirabegron | 19 | $23,670 |
| ProliaDenosumab | 13 | $22,286 |
| JanuviaSitagliptin Phosphate | 12 | $19,870 |
| JardianceEmpagliflozin | 19 | $18,379 |
| XareltoRivaroxaban | 14 | $18,133 |
| Rosuvastatin Calcium | 378 | $9,724 |
| LivaloPitavastatin Calcium | 16 | $9,671 |
| SynthroidLevothyroxine Sodium | 87 | $8,803 |
| Ezetimibe | 185 | $6,004 |
| Colesevelam Hcl | 11 | $4,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $90 | $47,94230 claims |
| PfizerEliquis | $153 | $42,40126 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $23,67019 claims |
| AmgenProlia | $1,340 | $22,28613 claims |
| MerckJanuvia | $40 | $19,87012 claims |
| Boehringer IngelheimJardiance | $193 | $18,37919 claims |
| Johnson & JohnsonXarelto | $119 | $18,13314 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $163 | $9,67116 claims |
| AbbVieSynthroid | $56 | $8,80387 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Lady Lake
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
- Kae FerberNaples$18K
- Stuti DangMiami$17K
- Angel HerreraNaples$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.